Clinical Trial Update: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sunitinib and cediranib for alveolar soft part sarcoma has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma

Drugs mentioned

• Cediranib (Cediranib)
• Sutent (sunitinib) (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Alveolar Soft Part | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19